

10/523553

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number TBA  
 Filing Date January 31, 2005  
 First Named Inventor Ferenc Buzsaky  
 Art Unit TBA-1615  
 Examiner Name TBA-HASAN S. AHMED  
 Attorney Docket Number 1103326-0786

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
HA		US-4,784,858	11-15-1988	Ventouras	
		US-5,292,522	03-08-1994	Petereit et al.	
		US-5,478,573	12-26-1995	Eichel et al.	
		US-5,871,776	02-16-1999	Mehta	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
HA		WO 02/058677-A1	08-01-2002	Hölzer et al.		
		WO 03/051340-A1	06-26-2003	Hjaristam et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
HA		LIN et al., AAPS Pharmasci., volume 3 (2), article 14, 2001, pages 1-12.	
		WESSELING et al., European Journal of Pharmaceutics and Biopharmaceutics, volume 47, no. 1, 1999, pages 73-78.	
		MATHIR et al., J. Microencapsulation, volume 14, no. 6, 1997, pages 743-751.	
		PETEREIT et al., European Journal of Pharmaceutics and Biopharmaceutics, volume 47, no. 1, 1999, pages 15-25.	
		PETEREIT et al., European Journal of Pharmaceutics and Biopharmaceutics, vol. 41, no. 4, August 1, 1995, pages 219-228.	
		RAGNARSSON et al., Drug Develop. and Ind. Pharmacy, vol. 13, pages 1495-1509 (1987).	
		SANDBERG et al., European Journal of Clin. Pharmacol., vol. 33 (1988), pages S3-S7 and S9-S14.	
		RAGNARSSON et al., International Journal of Pharmaceutics, vol. 79, pages 223-232 (1992).	
		SANDBERG et al., International Journal of Pharmaceutics, vol. 68, pages 167-177 (1991).	
HA		SANDBERG et al., Pharmaceutical Research, vol. 10, pages 28-34 (1993).	

Examiner Signature *HA* Date Considered 8 JANUARY 2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	TBA
Filing Date	January 31, 2005
First Named Inventor	Ferenc Buzsaky
Art Unit	TBA-1615
Examiner Name	TBA Thomas Schmed
Attorney Docket Number	1103326-0786

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
<i>Ha</i> ↑  ↓ <i>Ha</i>		SANDBERG et al., Drug Invest., vol. 6, pages 320-329 (1993).	
		AMIGHI AND MOËS, S.T.P. Pharma Sci., vol. 7(2), pages 141-147 (1997).	
		BODMEIER AND PAERATAKUL, Pharm. Res., vol. 11(6), pages 882-888 (1994).	
		OZTURK et al., J. Controlled Release, vol. 14, pages 203-213 (1990).	
		GOODHART et al., Pharmaceutical Tech., April 1984, pages 64-71.	
		BODMEIER AND PAERATAKUL, International Journal of Pharmaceutics, vol. 152, pages 17-26 (1997).	
		BODMEIER AND PAERATAKUL, Drug Develop. and Ind. Pharmacy, vol. 20(9), pages 1517-1533 (1994).	
		SPERLING et al., Journal of Applied Polymer Science, vol. 14, page 73-78 (1970).	
Examiner Signature		Date Considered	8 January 2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark where English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.94. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.